Experienced in Diffuse Large B-Cell Lymphoma (DLBCL)

Dr. William Bensinger

Oncology
Office
2940 S Meridian Ste 200, 
Puyallup, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
47 Years of Experience
Experienced in Diffuse Large B-Cell Lymphoma (DLBCL)
Office
2940 S Meridian Ste 200, 
Puyallup, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

William Bensinger is an Oncologist in Puyallup, Washington. Dr. Bensinger has been practicing medicine for over 47 years and is rated as an Experienced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 79 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in WA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Community Health
  • EPO
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PacificSource
  • PPO
Premera
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Office
2940 S Meridian Ste 200, Puyallup, WA 98373
Other Locations
Office
1221 Madison St Ste 1020, Seattle, WA 98104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: December 22, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin
Study Phase: Phase 1/Phase 2
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Procedure
Study Drugs: Lenalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 3
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Biological
Study Drugs: JCARH125, JCARH125 + Anakinra
Study Phase: Phase 1/Phase 2
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2023
Intervention Type: Drug
Study Drugs: Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone
Study Phase: Phase 2
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 22, 2023
Intervention Type: Drug
Study Drugs: AO-176, AO-176 + Dex, AO-176 + Dex + Bort
Study Phase: Phase 1/Phase 2
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2, Dose Escalation, Safety and Tolerability Study of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, Dose Escalation, Safety and Tolerability Study of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: April 01, 2021
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: August 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

79 Total Publications

Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 04, 2023
Similar Doctors
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Ajay K. Gopal
Oncology
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Ajay K. Gopal
Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (33.6 miles away)
206-288-1000
Languages Spoken:
English, Castilian, Hindi, Punjabi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Ajay Gopal is an Oncologist in Seattle, Washington. Dr. Gopal is rated as an Elite provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and B-Cell Lymphoma. Dr. Gopal is currently accepting new patients.

Brian G. Till
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Brian G. Till
Oncology
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Brian G. Till
Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (33.6 miles away)
206-288-1000
Languages Spoken:
English, Castilian, Filipino, French, Mandarin, Romanian, Russian, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Till is an Oncologist in Seattle, Washington. Dr. Till is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Follicular Lymphoma. Dr. Till is currently accepting new patients.

David M. Aboulafia
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. David M. Aboulafia
Oncology | Hematology
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. David M. Aboulafia
Oncology | Hematology

Virginia Mason Medical Center

1100 Ninth Avenue, 
Seattle, WA 
 (32.5 miles away)
206-624-1144
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Aboulafia, MD, has special interest in AIDS/HIV, viral syndromes, general hematology including coagulation and hemostasis, lympho and myeloproliferative disorder, leukemia, lymphoma, myeloma, primary and subspecialty, and HIV-associated malignancies, benign hematology including disorders of coagulation and thrombosis, HIV primary and subspecialty care AIDS defining (Kaposi's sarcoma, lymphoma) and HIV-associated cancer. Dr. Aboulafia is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Non-Hodgkin Lymphoma, Anal Cancer, Kaposi Sarcoma, B-Cell Lymphoma, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bensinger's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 46 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile